| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations (NCT05241873) | Blueprint Medicines Corporation | 2022-03-04 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
| External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446) | Blueprint Medicines Corporation | 2020-12-01 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04222972) | Hoffmann-La Roche | 2020-07-24 |
| Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer (NCT03331588) | Shanghai Pulmonary Hospital, Shanghai, China | 2017-11-10 |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (NCT03134872) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-12 |
| A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC (NCT03085069) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-03 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |
| Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients (NCT02804100) | Wenzhou Medical University | 2016-05-01 |
| The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial (NCT03402048) | University of Turin, Italy | 2012-07-01 |
| Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics (NCT02441972) | Wuxi No. 4 People's Hospital | 2012-01-01 |
| A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) (NCT00102505) | Pharmacyclics LLC. | 2004-11-01 |
| Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer (NCT01058785) | NovaRx Corporation | 2003-03-01 |